共有 50 笔近期内部人交易记录记录，涉及 Iovance Biotherapeutics, Inc. (IOVA), 包括 20 笔买入 和 28 笔卖出. 内部人买入总额为 $107.19K 内部人卖出总额为 $50.63K.
近期活跃的重要内部人包括 Bilinsky Igor, Vogt Frederick G, Graf Finckenstein Friedrich. 内部人交易记录可以揭示公司管理层对股票估值和未来前景的看法.
内部人交易记录 — IOVA
| 日期 |
姓名 |
职位 |
交易类型 |
股数 |
平均价格 |
总价值 |
持股数量 |
| 2026-03-09 |
Bilinsky Igor |
Chief Operating Officer |
限制性股票授予 (RSU) |
117,500 |
- |
- |
117,500 |
| 2026-03-09 |
Vogt Frederick G |
Interim CEO & General Counsel |
限制性股票授予 (RSU) |
235,000 |
- |
- |
235,000 |
| 2026-03-09 |
Graf Finckenstein Friedrich |
Chief Medical Officer |
限制性股票授予 (RSU) |
58,750 |
- |
- |
58,750 |
| 2026-03-09 |
Roche Corleen M. |
Chief Financial Officer |
限制性股票授予 (RSU) |
132,200 |
- |
- |
132,200 |
| 2026-03-09 |
Puri Raj K. |
Chief Regulatory Officer |
限制性股票授予 (RSU) |
117,500 |
- |
- |
117,500 |
| 2026-03-09 |
Kirby Daniel Gordon |
Chief Commercial Officer |
限制性股票授予 (RSU) |
132,200 |
- |
- |
132,200 |
| 2026-03-05 |
Bilinsky Igor |
Chief Operating Officer |
期权行权（卖出） |
31,246 |
- |
- |
62,504 |
| 2026-03-05 |
Vogt Frederick G |
Interim CEO & General Counsel |
期权行权（卖出） |
62,493 |
- |
- |
125,007 |
| 2026-03-05 |
Graf Finckenstein Friedrich |
Chief Medical Officer |
期权行权（卖出） |
31,246 |
- |
- |
62,504 |
| 2026-03-05 |
Puri Raj K. |
Chief Regulatory Officer |
期权行权（卖出） |
39,059 |
- |
- |
78,131 |
| 2026-03-02 |
Bilinsky Igor |
Chief Operating Officer |
期权行权（卖出） |
3,517 |
- |
- |
- |
| 2026-03-02 |
Vogt Frederick G |
Interim CEO & General Counsel |
期权行权（卖出） |
10,418 |
- |
- |
- |
| 2026-03-02 |
Graf Finckenstein Friedrich |
Chief Medical Officer |
期权行权（卖出） |
3,907 |
- |
- |
- |
| 2026-03-02 |
Puri Raj K. |
Chief Regulatory Officer |
期权行权（卖出） |
5,470 |
- |
- |
21,878 |
| 2026-02-24 |
Kirby Daniel Gordon |
Chief Commercial Officer |
期权行权（卖出） |
150,000 |
- |
- |
- |
| 2026-02-10 |
Kirby Daniel Gordon |
Chief Commercial Officer |
RSU 预扣税 |
16,450 |
$2.60 |
$42.77K |
53,546 |
| 2025-12-02 |
Bilinsky Igor |
Chief Operating Officer |
期权行权（卖出） |
3,516 |
- |
- |
3,517 |
| 2025-12-02 |
Vogt Frederick G |
Interim CEO & General Counsel |
期权行权（卖出） |
10,417 |
- |
- |
10,418 |
| 2025-12-02 |
Graf Finckenstein Friedrich |
Chief Medical Officer |
期权行权（卖出） |
3,906 |
- |
- |
3,907 |
| 2025-12-01 |
Bilinsky Igor |
Chief Operating Officer |
期权行权（卖出） |
8,789 |
- |
- |
43,949 |
| 2025-12-01 |
Vogt Frederick G |
Interim CEO & General Counsel |
期权行权（卖出） |
41,669 |
- |
- |
208,344 |
| 2025-12-01 |
Graf Finckenstein Friedrich |
Chief Medical Officer |
期权行权（卖出） |
8,789 |
- |
- |
43,949 |
| 2025-12-01 |
Puri Raj K. |
Chief Regulatory Officer |
期权行权（卖出） |
5,469 |
- |
- |
27,348 |
| 2025-09-02 |
Bilinsky Igor |
Chief Operating Officer |
期权行权（卖出） |
3,516 |
- |
- |
7,033 |
| 2025-09-02 |
Vogt Frederick G |
Interim CEO & General Counsel |
期权行权（卖出） |
10,417 |
- |
- |
20,385 |
| 2025-09-02 |
Graf Finckenstein Friedrich |
Chief Medical Officer |
期权行权（卖出） |
3,907 |
- |
- |
7,813 |
| 2025-09-02 |
Puri Raj K. |
Chief Regulatory Officer |
期权行权（卖出） |
5,470 |
- |
- |
32,817 |
| 2025-08-06 |
Roche Corleen M. |
Officer |
未知 |
- |
- |
- |
- |
| 2025-08-06 |
Roche Corleen M. |
Chief Financial Officer |
限制性股票授予 (RSU) |
150,000 |
- |
- |
150,000 |
| 2025-06-30 |
Rosinack Matthew W. |
SVP, Finance (int. Pfo & Pao) |
未知 |
75,000 |
$25.30 |
$1.9M |
- |
| 2025-06-13 |
Yarno Wendy L |
Director |
限制性股票授予 (RSU) |
67,546 |
- |
- |
67,546 |
| 2025-06-13 |
Weiser Michael |
Director |
限制性股票授予 (RSU) |
67,546 |
- |
- |
67,546 |
| 2025-06-13 |
Maynard Ryan D |
Director |
限制性股票授予 (RSU) |
67,546 |
- |
- |
67,546 |
| 2025-06-13 |
Countouriotis Athena |
Director |
限制性股票授予 (RSU) |
67,546 |
- |
- |
67,546 |
| 2025-06-13 |
Dukes Iain D. |
Director |
限制性股票授予 (RSU) |
135,092 |
- |
- |
135,092 |
| 2025-06-05 |
Kirby Daniel Gordon |
Chief Commercial Officer |
知情买入 |
30,000 |
$1.84 |
$55.2K |
30,000 |
| 2025-06-02 |
Bilinsky Igor |
Chief Operating Officer |
期权行权（卖出） |
3,516 |
- |
- |
10,549 |
| 2025-06-02 |
Vogt Frederick G |
Interim CEO & General Counsel |
期权行权（卖出） |
10,417 |
- |
- |
31,252 |
| 2025-06-02 |
Bellemin Jean-marc |
Chief Financial Officer |
RSU 预扣税 |
4,464 |
$1.76 |
$7.86K |
60,529 |
| 2025-06-02 |
Graf Finckenstein Friedrich |
Chief Medical Officer |
期权行权（卖出） |
3,906 |
- |
- |
11,720 |
| 2025-06-02 |
Puri Raj K. |
Chief Regulatory Officer |
期权行权（卖出） |
5,469 |
- |
- |
38,287 |
| 2025-05-23 |
Puri Raj K. |
Chief Regulatory Officer |
知情买入 |
5,600 |
$1.74 |
$9.74K |
206,852 |
| 2025-05-14 |
Vogt Frederick G |
Interim CEO & General Counsel |
知情买入 |
25,000 |
$1.69 |
$42.25K |
374,646 |
| 2025-03-14 |
Puri Raj K. |
Chief Regulatory Officer |
期权行权（卖出） |
8,334 |
- |
- |
- |
| 2025-03-05 |
Bilinsky Igor |
Chief Operating Officer |
限制性股票授予 (RSU) |
93,750 |
- |
- |
93,750 |
| 2025-03-05 |
Vogt Frederick G |
Interim CEO & General Counsel |
限制性股票授予 (RSU) |
187,500 |
- |
- |
187,500 |
| 2025-03-05 |
Bellemin Jean-marc |
Chief Financial Officer |
限制性股票授予 (RSU) |
93,750 |
- |
- |
93,750 |
| 2025-03-05 |
Graf Finckenstein Friedrich |
Chief Medical Officer |
限制性股票授予 (RSU) |
93,750 |
- |
- |
93,750 |
| 2025-03-05 |
Puri Raj K. |
Chief Regulatory Officer |
限制性股票授予 (RSU) |
117,190 |
- |
- |
117,190 |
| 2025-03-03 |
Bilinsky Igor |
Chief Operating Officer |
期权行权（卖出） |
3,516 |
- |
- |
14,065 |
■ 知情交易 — 公开市场买卖（最具参考价值）
■ 非知情买入 — 奖励、期权行权、转换
■ 非知情卖出 — 税务代扣、归属出售
■ 中性 — 礼赠、信托、到期
